Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
|Articles|August 1, 2001
- Pharmaceutical Technology-08-01-2001
- Volume 2001 Supplement
- Issue 2
The Squeeze in Contract Manufacturing
Author(s)Scott Fogerty, Roger Lias
The demand for CGMP production of biopharmaceuticals is at an all-time high.
Advertisement
Articles in this issue
about 25 years ago
Creating a Successful Partnership with a Contract Manufacturerabout 25 years ago
Outsourcing Outlookabout 25 years ago
Creative Solutions in Client-CRO Relationshipsabout 25 years ago
Third-Party Technology Transferabout 25 years ago
Stakes Rise for Blown Batchesabout 25 years ago
Partnerships in Drug DiscoveryAdvertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech AI Pulse Check: Fixing AI Slop at the Source
4
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
5